title: Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy.
abstract: OBJECTIVE
  While androgen deprivation therapy (ADT) has been associated with decreased quality of life (QoL), controlled prospective studies are lacking. We aimed to assess QoL during ADT using two validated questionnaires and determine contributing factors.
  
  
  METHODS
  Prospective controlled study.
  
  
  METHODS
  Sixty-three men with nonmetastatic prostate cancer newly commencing ADT (n = 34) and age- and radiotherapy-matched prostate cancer controls (n = 29).
  
  
  METHODS
  QoL was measured by Short-Form 12 version 2 survey (SF-12) and Aging Males' Symptoms (AMS) score at 0, 6 and 12 months. Generalized linear models determined the mean adjusted difference (MAD) (95% confidence interval) between groups during follow-up.
  
  
  RESULTS
  Compared to controls over 12 months, men receiving ADT had decreased SF-12 physical component score [MAD -3·61 (-6·94, -0·29), P = 0·013] reflecting worsening QoL but no change in the mental component (P = 0·74). Total AMS score increased [MAD 9·35 (5·65, 13·07), P < 0·001], reflecting worse QoL. Both SF-12 and AMS changes were greater than reported minimum clinically important differences. AMS sub-domains showed increased somatic [MAD 3·96 (1·94, 5·99), P < 0·001] and sexual [MAD 3·80 (2·16, 5·44), P < 0·001] components but not psychological (P = 0·19). Decrements were related to an increase in hot flushes (P = 0·016) but not haemoglobin decrease (P = 0·46).
  
  
  CONCLUSIONS
  Within 12 months, ADT is associated with clinically significant decreased QoL, particularly physical and sexual aspects, independent of the confounding effects of a cancer diagnosis or radiotherapy. As QoL is a crucial aspect of prostate cancer treatment, addressing hot flushes, sexual dysfunction and exercise may potentially improve outcomes for men undergoing ADT.
authors.affiliation: Department of Medicine, The University of Melbourne, Heidelberg, Vic., Australia.|Department of Endocrinology, Austin Health, Heidelberg, Vic., Australia.
authors.forename: Ada S
authors.identifier: http://orcid.org/0000-0001-5257-5525
authors.initials: AS
authors.lastname: Cheung
authors.affiliation: Department of Medicine, The University of Melbourne, Heidelberg, Vic., Australia.
authors.forename: Casey
authors.initials: C
authors.lastname: de Rooy
authors.affiliation: Department of Endocrinology, Austin Health, Heidelberg, Vic., Australia.
authors.forename: Rudolf
authors.initials: R
authors.lastname: Hoermann
authors.affiliation: Department of Radiation Oncology, Austin Health, Heidelberg, Vic., Australia.
authors.forename: Daryl
authors.initials: D
authors.lastname: Lim Joon
authors.affiliation: Department of Medicine, The University of Melbourne, Heidelberg, Vic., Australia.|Department of Endocrinology, Austin Health, Heidelberg, Vic., Australia.
authors.forename: Jeffrey D
authors.initials: JD
authors.lastname: Zajac
authors.affiliation: Department of Medicine, The University of Melbourne, Heidelberg, Vic., Australia.|Department of Endocrinology, Austin Health, Heidelberg, Vic., Australia.
authors.forename: Mathis
authors.initials: M
authors.lastname: Grossmann
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D016022:Case-Control Studies; D015444:Exercise; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000523:psychology*; D011788:Quality of Life; D012735:Sexual Dysfunction, Physiological; D011795:Surveys and Questionnaires
chemical_list: D000726:Androgen Antagonists